naltrexone and D-fructopyranose

naltrexone has been researched along with D-fructopyranose in 64 studies

Research

Studies (64)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	20 (31.25)	29.6817
2010's	43 (67.19)	24.3611
2020's	1 (1.56)	2.80

Authors

Authors	Studies
Salaspuro, M	1
Baker, RW; Bodnar, RJ; Lee, MG; Li, Y; Sclafani, A	1
Anton, R; Myrick, H	1
Kenna, GA; McGeary, JE; Swift, RM	1
Egli, M; Heilig, M	1
Pettinati, HM; Rabinowitz, AR	1
Roesner, S; Soyka, M	1
Johnson, BA	2
Dannon, PN; Gonopolsky, Y; Kotler, M; Lowengrub, K; Musin, E	1
Kuehn, BM	1
Berglund, M; Gorelick, D; Hesselbrock, V; Johnson, BA; Kranzler, HR; Möller, HJ; Soyka, M	1
Alvarez, S; Bobes, J; Flórez, G; García-Portilla, P; Nogueiras, L; Saiz, PA	3
Baltieri, DA; Daró, FR; de Andrade, AG; Ribeiro, PL	2
Garbutt, JC	1
Andrade, AG; Baltieri, DA; Daró, FR; Ribeiro, PL	1
Basu, D; Shah, R	1
de Silva, V; Hanwella, R	1
Falk, D; Fertig, J; Johnson, B; Litten, RZ; Liu, L; Mattson, M; Ryan, M; Stout, R; Wang, XQ	1
Bray, GA; Ryan, DH	1
Goldfine, AB; Hiatt, WR; Thomas, A	1
Book, SW; Miller, PM; Stewart, SH	1
Chen, J; Isaac, M; Johnson, BA; Liu, L; O'Quigley, J; Wang, XQ; Zhang, D	1
Carter, R; Mouralidarane, A; Oben, J; Ray, S; Soeda, J	1
Manzanares, J; Navarrete, F; Rubio, G	1
O'Connor, PG; O'Malley, SS	1
Howland, RH	1
Gillman, AG; Kosobud, AE; Leffel, JK; Timberlake, W	1
Aubin, HJ; Daeppen, JB	1
Johnson, BA; Lynch, WJ; Moore, CF; Protzuk, OA	1
Heinz, A; Müller, CA	1
Badalia, A; Bodnar, RJ; Duenas, SM; Hossain, M; Rotella, FM; Saeed, S; Sclafani, A; Touzani, K	1
Banakos, T; Bernal, SY; Bodnar, RJ; Malkusz, DC; Malkusz, G; Mohamed, A; Vongwattanakit, T	1
Anton, RF; Falk, DE; Johnson, BA; Kranzler, HR; Litten, RZ	1
Nakazato, M; Ueno, H	1
Amick, HR; Bobashev, G; Feltner, C; Garbutt, JC; Gass, CE; Jonas, DE; Kim, MM; Rowe, CJ; Shanahan, E; Thomas, K; Wines, R	1
Liang, J; Olsen, RW	1
Aldhoon-Hainerová, I; Hainer, V	1
Hainer, V	1
Cunningham, JW; Wiviott, SD	1
Goutier, W; Kloeze, M; McCreary, AC	1
Citrome, L	1
Rubio, MA	1
Mehr, SR; Zimmerman, MP	1
Bodnar, RJ; Huang, D; Kraft, TT; La Magna, S; Lolier, M; Natanova, E; Sclafani, A; Warshaw, D; Yakubov, Y	1
Dahiya, N; Kakkar, AK	1
Fujioka, K	1
Bragg, R; Crannage, E	1
Bodnar, RJ; Fitzgerald, G; Huang, D; Kraft, TT; Natanova, E; Sclafani, A; Yakubov, Y	1
Helton, SG; Lohoff, FW	1
Megyeri, J; Nuffer, W; Trujillo, JM	1
Camilleri, M; Chandar, AK; Dulai, PS; Khera, R; Loomba, R; Murad, MH; Prokop, LJ; Singh, S; Wang, Z	1
Bowe, T; Christopher, M; Finlay, AK; Gidwani, R; Hagedorn, H; Harris, AH; Kay, C; Nevedal, A; Rosen, C	1
Halpern, B; Mancini, MC	1
Aronne, LJ; Igel, LI; Kumar, RB; Saunders, KH	1
Goh, ET; Morgan, MY	1
Curry, SA	1
Lyon, J	1
Berghold, A; Horvath, K; Jeitler, K; Krenn, C; Semlitsch, T; Siebenhofer, A; Winterholer, S	1

Reviews

30 review(s) available for naltrexone and D-fructopyranose

Article	Year
[Drug therapy of alcohol dependence--a critical review]. Duodecim; laaketieteellinen aikakauskirja, 2003, Volume: 119, Issue:24 Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Anticonvulsants; Fructose; Humans; Naltrexone; Narcotic Antagonists; Randomized Controlled Trials as Topic; Taurine; Topiramate	2003
Recent advances in the pharmacotherapy of alcoholism. Current psychiatry reports, 2004, Volume: 6, Issue:5 Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Anticonvulsants; Clinical Trials as Topic; Fructose; Humans; Naltrexone; Narcotic Antagonists; Neurotransmitter Agents; Taurine; Topiramate	2004
Pharmacotherapy, pharmacogenomics, and the future of alcohol dependence treatment, Part 2. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2004, Nov-15, Volume: 61, Issue:22 Topics: Alcohol Deterrents; Alcoholism; Aripiprazole; Behavior Therapy; Disulfiram; Fructose; Humans; Naltrexone; Ondansetron; Pharmacogenetics; Piperazines; Quinolones; Topiramate	2004
Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms. Pharmacology & therapeutics, 2006, Volume: 111, Issue:3 Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Baclofen; Corticotropin-Releasing Hormone; Disease Models, Animal; Disulfiram; Fructose; Humans; Naltrexone; Neuropeptide Y; Nociceptin; Ondansetron; Opioid Peptides; Receptor, Cannabinoid, CB1; Receptor, Metabotropic Glutamate 5; Receptors, Metabotropic Glutamate; Taurine; Topiramate	2006
Choosing the right medication for the treatment of alcoholism. Current psychiatry reports, 2006, Volume: 8, Issue:5 Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Choice Behavior; Cognitive Behavioral Therapy; Combined Modality Therapy; Fructose; Humans; Naltrexone; Narcotic Antagonists; Neuroprotective Agents; Taurine; Topiramate	2006
New pharmacological approaches for the treatment of alcoholism. Expert opinion on pharmacotherapy, 2006, Volume: 7, Issue:17 Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Carbamazepine; Depression; Disease Models, Animal; Disulfiram; Fructose; Humans; Naltrexone; Secondary Prevention; Taurine; Topiramate	2006
Update on neuropharmacological treatments for alcoholism: scientific basis and clinical findings. Biochemical pharmacology, 2008, Jan-01, Volume: 75, Issue:1 Topics: Acamprosate; Alcoholism; Animals; Baclofen; Disulfiram; Fructose; Humans; Naltrexone; Ondansetron; Receptors, N-Methyl-D-Aspartate; Ritanserin; Selective Serotonin Reuptake Inhibitors; Taurine; Topiramate	2008
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Substance Use and Related Disorders, Part 1: Alcoholism. The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, 2008, Volume: 9, Issue:1 Topics: Acamprosate; Alcohol Deterrents; Alcohol-Related Disorders; Biological Psychiatry; Carbamazepine; Disulfiram; Fructose; Health Planning Guidelines; Humans; Naltrexone; Ondansetron; Societies, Scientific; Substance-Related Disorders; Taurine; Topiramate	2008
The state of pharmacotherapy for the treatment of alcohol dependence. Journal of substance abuse treatment, 2009, Volume: 36, Issue:1 Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Baclofen; Delayed-Action Preparations; Disulfiram; Fructose; Humans; Medication Adherence; Naltrexone; Taurine; Temperance; Topiramate	2009
Medication treatment of different types of alcoholism. The American journal of psychiatry, 2010, Volume: 167, Issue:6 Topics: Adult; Aged; Alcohol Deterrents; Alcoholism; Baclofen; Chronic Disease; Depressive Disorder; Female; Fructose; Humans; Hypothalamo-Hypophyseal System; Limbic System; Male; Naltrexone; Ondansetron; Pituitary-Adrenal System; Prefrontal Cortex; Receptors, Dopamine D2; Receptors, GABA; Topiramate; Young Adult	2010
Medical treatment of alcohol dependence: a systematic review. International journal of psychiatry in medicine, 2011, Volume: 42, Issue:3 Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Disulfiram; Fructose; Humans; Naltrexone; Narcotic Antagonists; Off-Label Use; Taurine; Topiramate; Treatment Outcome	2011
Recent advancements in drug treatment of obesity. Clinical medicine (London, England), 2012, Volume: 12, Issue:5 Topics: Anti-Obesity Agents; Benzazepines; Benzoxazines; Bupropion; Clinical Trials as Topic; Drug Combinations; Fructose; Glucagon-Like Peptide 1; Humans; Lactones; Life Style; Liraglutide; Naltrexone; Obesity; Orlistat; Phentermine; Topiramate; Weight Loss	2012
Medications for unhealthy alcohol use: across the spectrum. Alcohol research & health : the journal of the National Institute on Alcohol Abuse and Alcoholism, 2011, Volume: 33, Issue:4 Topics: Acamprosate; Alcohol Drinking; Alcoholism; Animals; Disulfiram; Dopamine Agents; Fructose; Humans; Naltrexone; Selective Serotonin Reuptake Inhibitors; Taurine; Topiramate	2011
Emerging pharmacotherapies for alcohol dependence: a systematic review focusing on reduction in consumption. Drug and alcohol dependence, 2013, Nov-01, Volume: 133, Issue:1 Topics: Alcohol Abstinence; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Aripiprazole; Flupenthixol; Fluvoxamine; Fructose; Humans; Naltrexone; Piperazines; Psychotropic Drugs; Quinolones; Topiramate	2013
[New treatment options for alcohol dependence]. MMW Fortschritte der Medizin, 2013, May-02, Volume: 155, Issue:8 Topics: Acamprosate; Alcoholism; Baclofen; Combined Modality Therapy; Ethanol; Fructose; Humans; Naltrexone; Psychotherapy; Secondary Prevention; Socioenvironmental Therapy; Substance Withdrawal Syndrome; Taurine; Topiramate	2013
[Cutting-edge of medicine; the prospects of novel anti-obesity drugs]. Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 2014, Mar-10, Volume: 103, Issue:3 Topics: Anti-Obesity Agents; Appetite; Appetite Depressants; Benzazepines; Benzoxazines; Bupropion; Clinical Trials as Topic; Drug Approval; Drug Combinations; Drug Discovery; Energy Metabolism; Enzyme Inhibitors; Fructose; Glucagon-Like Peptide 1; Humans; Hypothalamus; Lactones; Lipase; Liraglutide; Metabolic Syndrome; Naltrexone; Obesity; Orlistat; Phentermine; Topiramate	2014
Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis. JAMA, 2014, May-14, Volume: 311, Issue:18 Topics: Acamprosate; Alcohol-Related Disorders; Fructose; Harm Reduction; Humans; Naltrexone; Outpatients; Randomized Controlled Trials as Topic; Taurine; Topiramate	2014
Alcohol use disorders and current pharmacological therapies: the role of GABA(A) receptors. Acta pharmacologica Sinica, 2014, Volume: 35, Issue:8 Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Animals; Benzodiazepines; Disulfiram; Ethanol; Fructose; Humans; Naltrexone; Narcotic Antagonists; Neuroprotective Agents; Plant Preparations; Receptors, GABA-A; Taurine; Topiramate	2014
Tolerability and safety of the new anti-obesity medications. Drug safety, 2014, Volume: 37, Issue:9 Topics: Anti-Obesity Agents; Benzazepines; Benzoxazines; Bupropion; Chemistry, Pharmaceutical; Drug-Related Side Effects and Adverse Reactions; Fructose; Glucagon-Like Peptide 1; Humans; Liraglutide; Naltrexone; Obesity; Phentermine; Topiramate	2014
Overview of new antiobesity drugs. Expert opinion on pharmacotherapy, 2014, Volume: 15, Issue:14 Topics: Anti-Obesity Agents; Benzazepines; Benzoxazines; Bupropion; Drug Combinations; Fructose; Glucagon-Like Peptide 1; Humans; Liraglutide; Naltrexone; Obesity; Phentermine; Topiramate; Weight Loss	2014
Modern obesity pharmacotherapy: weighing cardiovascular risk and benefit. Clinical cardiology, 2014, Volume: 37, Issue:11 Topics: Anti-Obesity Agents; Benzazepines; Bupropion; Cardiovascular Diseases; Clinical Trials as Topic; Drug Combinations; Fructose; Heart; Humans; Naltrexone; Obesity; Phentermine; Topiramate	2014
Drug treatment of obesity: current status and future prospects. European journal of internal medicine, 2015, Volume: 26, Issue:2 Topics: Anti-Obesity Agents; Benzazepines; Bupropion; Drug Combinations; Drug Therapy, Combination; Fructose; Humans; Lactones; Naltrexone; Obesity; Orlistat; Phentermine; Topiramate	2015
Safety and tolerability of medications approved for chronic weight management. Obesity (Silver Spring, Md.), 2015, Volume: 23 Suppl 1 Topics: Anti-Obesity Agents; Benzazepines; Bupropion; Delayed-Action Preparations; Drug-Related Side Effects and Adverse Reactions; Drugs, Investigational; Fructose; Glucagon-Like Peptide 1; Humans; Liraglutide; Naltrexone; Obesity; Phentermine; Topiramate; United States; United States Food and Drug Administration; Weight Loss	2015
Pharmacogenetics of alcohol use disorders and comorbid psychiatric disorders. Psychiatry research, 2015, Dec-15, Volume: 230, Issue:2 Topics: Acamprosate; Alcohol Deterrents; Alcohol-Related Disorders; Anxiety Disorders; Comorbidity; Depressive Disorder, Major; Disulfiram; Fructose; Humans; Naltrexone; Pharmacogenetics; Precision Medicine; Taurine; Topiramate; United States	2015
A Comparison of New Pharmacological Agents for the Treatment of Obesity. The Annals of pharmacotherapy, 2016, Volume: 50, Issue:5 Topics: Anti-Obesity Agents; Benzazepines; Bupropion; Clinical Trials, Phase III as Topic; Drug Combinations; Fructose; Humans; Liraglutide; Naltrexone; Obesity; Phentermine; Topiramate; Weight Loss	2016
Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis. JAMA, 2016, Jun-14, Volume: 315, Issue:22 Topics: Anti-Obesity Agents; Bayes Theorem; Benzazepines; Drug Combinations; Female; Fructose; Humans; Lactones; Liraglutide; Male; Middle Aged; Naltrexone; Obesity; Orlistat; Phentermine; Randomized Controlled Trials as Topic; Topiramate; Weight Loss	2016
Safety assessment of combination therapies in the treatment of obesity: focus on naltrexone/bupropion extended release and phentermine-topiramate extended release. Expert opinion on drug safety, 2017, Volume: 16, Issue:1 Topics: Animals; Anti-Obesity Agents; Bupropion; Delayed-Action Preparations; Drug Combinations; Fructose; Humans; Naltrexone; Obesity; Phentermine; Topiramate	2017
Practical Use of Pharmacotherapy for Obesity. Gastroenterology, 2017, Volume: 152, Issue:7 Topics: Androgens; Anti-Obesity Agents; Antidepressive Agents; Antihypertensive Agents; Antipsychotic Agents; Appetite Depressants; Benzazepines; Bupropion; Drug Combinations; Fructose; Humans; Hypoglycemic Agents; Hypogonadism; Lactones; Liraglutide; Naltrexone; Obesity; Orlistat; Phentermine; Testosterone; Topiramate; Weight Gain	2017
Review article: pharmacotherapy for alcohol dependence - the why, the what and the wherefore. Alimentary pharmacology & therapeutics, 2017, Volume: 45, Issue:7 Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Baclofen; Disulfiram; Drug Combinations; Fructose; Humans; Naltrexone; Polymorphism, Single Nucleotide; Pyridoxine; Pyrrolidonecarboxylic Acid; Taurine; Topiramate; Treatment Outcome	2017
Long-term effects of weight-reducing drugs in people with hypertension. The Cochrane database of systematic reviews, 2021, 01-17, Volume: 1 Topics: Adult; Anti-Obesity Agents; Appetite Depressants; Bias; Blood Pressure; Body Weight; Bupropion; Diet, Reducing; Drug Combinations; Female; Fructose; Humans; Hypertension; Lactones; Male; Middle Aged; Naltrexone; Orlistat; Phentermine; Piperidines; Pyrazoles; Randomized Controlled Trials as Topic; Safety-Based Drug Withdrawals; Time; Topiramate	2021

Trials

7 trial(s) available for naltrexone and D-fructopyranose

Article	Year
Using topiramate or naltrexone for the treatment of alcohol-dependent patients. Alcoholism, clinical and experimental research, 2008, Volume: 32, Issue:7 Topics: Adult; Alcoholism; Female; Fructose; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Neuroprotective Agents; Psychological Tests; Severity of Illness Index; Topiramate	2008
Comparing topiramate with naltrexone in the treatment of alcohol dependence. Addiction (Abingdon, England), 2008, Volume: 103, Issue:12 Topics: Adolescent; Adult; Alcohol Deterrents; Alcoholism; Double-Blind Method; Fructose; Humans; Male; Middle Aged; Naltrexone; Patient Compliance; Socioeconomic Factors; Topiramate; Treatment Outcome; Young Adult	2008
The role of alcoholic beverage preference in the severity of alcohol dependence and adherence to the treatment. Alcohol (Fayetteville, N.Y.), 2009, Volume: 43, Issue:3 Topics: Adolescent; Adult; Alcoholic Beverages; Alcoholism; Beer; Fructose; Humans; Male; Middle Aged; Motivation; Naltrexone; Narcotic Antagonists; Patient Compliance; Topiramate; Treatment Outcome	2009
Effects of topiramate or naltrexone on tobacco use among male alcohol-dependent outpatients. Drug and alcohol dependence, 2009, Nov-01, Volume: 105, Issue:1-2 Topics: Adolescent; Adult; Alcoholism; Analysis of Variance; Anticonvulsants; Dose-Response Relationship, Drug; Double-Blind Method; Fructose; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Outpatients; Patient Compliance; Secondary Prevention; Smoking; Smoking Cessation; Socioeconomic Factors; Topiramate; Treatment Outcome; Young Adult	2009
Topiramate for the treatment of alcohol dependence: comparison with naltrexone. European addiction research, 2011, Volume: 17, Issue:1 Topics: Alcohol Drinking; Alcoholism; Excitatory Amino Acid Agents; Female; Fructose; Humans; Male; Medication Adherence; Middle Aged; Naltrexone; Quality of Life; Time Factors; Topiramate; Treatment Outcome	2011
Trajectory analyses in alcohol treatment research. Alcoholism, clinical and experimental research, 2012, Volume: 36, Issue:8 Topics: Acamprosate; Adult; Aged; Aged, 80 and over; Alcohol Deterrents; Alcoholism; Algorithms; Behavior Therapy; Combined Modality Therapy; Data Interpretation, Statistical; Double-Blind Method; Female; Fructose; Humans; Linear Models; Male; Middle Aged; Models, Statistical; Naltrexone; Narcotic Antagonists; Neuroprotective Agents; Nonlinear Dynamics; Regression Analysis; Research; Research Design; Taurine; Topiramate; Treatment Outcome; Young Adult	2012
Cumulative proportion of responders analysis (CPRA) as a tool to assess treatment outcome in alcohol clinical trials. Journal of studies on alcohol and drugs, 2014, Volume: 75, Issue:2 Topics: Alcohol Deterrents; Alcohol Drinking; Alcoholism; Double-Blind Method; Fructose; Humans; Naltrexone; Narcotic Antagonists; Topiramate; Treatment Outcome	2014

Other Studies

27 other study(ies) available for naltrexone and D-fructopyranose

Article	Year
Naltrexone does not prevent acquisition or expression of flavor preferences conditioned by fructose in rats. Pharmacology, biochemistry, and behavior, 2004, Volume: 78, Issue:2 Topics: Animals; Conditioning, Psychological; Dose-Response Relationship, Drug; Fructose; Male; Naltrexone; Rats; Rats, Sprague-Dawley; Taste	2004
Drug treatment for alcoholism today. The Harvard mental health letter, 2005, Volume: 22, Issue:1 Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Antidepressive Agents; Disulfiram; Fructose; Humans; Naltrexone; Substance Withdrawal Syndrome; Taurine; Topiramate	2005
12-month follow-up study of drug treatment in pathological gamblers: a primary outcome study. Journal of clinical psychopharmacology, 2007, Volume: 27, Issue:6 Topics: Adolescent; Adult; Analysis of Variance; Bupropion; Delayed-Action Preparations; Drug Therapy; Fluvoxamine; Follow-Up Studies; Fructose; Gambling; Humans; Israel; Male; Middle Aged; Naltrexone; Outcome Assessment, Health Care; Psychiatric Status Rating Scales; Psychopharmacology; Recurrence; Reproducibility of Results; Surveys and Questionnaires; Time Factors; Topiramate	2007
New therapies for alcohol dependence open options for office-based treatment. JAMA, 2007, Dec-05, Volume: 298, Issue:21 Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Behavior Therapy; Disulfiram; Family Practice; Fructose; Humans; Naltrexone; Taurine; Topiramate	2007
Topiramate: 'small is beautiful'? Addiction (Abingdon, England), 2009, Volume: 104, Issue:8 Topics: Alcohol Deterrents; Alcohol-Related Disorders; Fructose; Humans; Naltrexone; Topiramate; Treatment Outcome	2009
Treatment of alcohol dependence. The Ceylon medical journal, 2009, Volume: 54, Issue:2 Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Disulfiram; Fructose; Humans; Naltrexone; Narcotic Antagonists; Neuroprotective Agents; Taurine; Topiramate; Vitamins	2009
Alcohol dependence: after the withdrawal phase. Long-term abstinence: better health and psychosocial status. Psychosocial support for a chronic disorder. Some drugs are useful adjuncts to medical support. Prescrire international, 2009, Volume: 18, Issue:103 Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcohol-Related Disorders; Alcoholics; Alcoholism; Anticonvulsants; Baclofen; Clinical Trials as Topic; Combined Modality Therapy; Disulfiram; France; Fructose; Health Status; Humans; Naltrexone; Psychotherapy; Randomized Controlled Trials as Topic; Secondary Prevention; Self-Help Groups; Social Support; Taurine; Temperance; Topiramate; Treatment Outcome	2009
Percentage of subjects with no heavy drinking days: evaluation as an efficacy endpoint for alcohol clinical trials. Alcoholism, clinical and experimental research, 2010, Volume: 34, Issue:12 Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Female; Fructose; Humans; Male; Naltrexone; Randomized Controlled Trials as Topic; Taurine; Temperance; Time Factors; Topiramate; Treatment Outcome	2010
[Amisulpride for the treatment of alcohol dependence]. Adicciones, 2011, Volume: 23, Issue:2 Topics: Alcoholism; Amisulpride; Anticonvulsants; Antipsychotic Agents; Female; Fructose; Humans; Male; Naltrexone; Narcotic Antagonists; Sulpiride; Topiramate	2011
Drug treatment of obesity. The Psychiatric clinics of North America, 2011, Volume: 34, Issue:4 Topics: Adolescent; Adult; Anti-Obesity Agents; Antidepressive Agents, Second-Generation; Body Weight; Bupropion; Child; Drug Approval; Drug Combinations; Energy Intake; Exenatide; Female; Fructose; Humans; Hypoglycemic Agents; Islet Amyloid Polypeptide; Lactones; Male; Metformin; Naltrexone; Narcotic Antagonists; Obesity; Orlistat; Patient Compliance; Peptides; Randomized Controlled Trials as Topic; Sympathomimetics; Topiramate; United States; United States Food and Drug Administration; Venoms	2011
What cost weight loss? Circulation, 2012, Mar-06, Volume: 125, Issue:9 Topics: Anti-Obesity Agents; Benzazepines; Bupropion; Cyclobutanes; Fructose; Humans; Naltrexone; Obesity; Phentermine; Risk Assessment; Risk Factors; Topiramate; Weight Loss	2012
Effects of naltrexone plus topiramate on ethanol self-administration and tyrosine hydroxylase gene expression changes. Addiction biology, 2014, Volume: 19, Issue:5 Topics: Administration, Oral; Alcohol Drinking; Analysis of Variance; Animals; Central Nervous System Agents; Central Nervous System Depressants; Conditioning, Operant; Drug Combinations; Ethanol; Fructose; Gene Expression; Mice, Inbred C57BL; Motivation; Naltrexone; Self Administration; Topiramate; Tyrosine 3-Monooxygenase; Ventral Tegmental Area	2014
Therapies for obesity and medication-associated weight gain. Journal of psychosocial nursing and mental health services, 2013, Volume: 51, Issue:5 Topics: Animals; Appetite Depressants; Bariatric Surgery; Benzazepines; Bupropion; Chronic Disease; Combined Modality Therapy; Diet, Reducing; Disease Models, Animal; Drug Combinations; Exercise; Fructose; Humans; Mood Disorders; Naltrexone; Obesity; Overweight; Phentermine; Psychotic Disorders; Randomized Controlled Trials as Topic	2013
Behavioral characteristics and pharmacological manipulations of a nicotine-entrainable circadian oscillator. Chronobiology international, 2013, Volume: 30, Issue:7 Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Behavior, Animal; Benzoxazoles; Circadian Rhythm; Feeding Behavior; Female; Fructose; Light; Motor Activity; Naltrexone; Naphthyridines; Narcotic Antagonists; Nicotine; Nicotinic Agonists; Oscillometry; Rats; Rats, Sprague-Dawley; Time Factors; Topiramate; Urea	2013
The efficacy of a low dose combination of topiramate and naltrexone on ethanol reinforcement and consumption in rat models. Pharmacology, biochemistry, and behavior, 2014, Volume: 116 Topics: Alcohol Drinking; Animals; Dose-Response Relationship, Drug; Drug Combinations; Ethanol; Fructose; Models, Animal; Naltrexone; Rats; Rats, Wistar; Topiramate	2014
Role of NMDA, opioid and dopamine D1 and D2 receptor signaling in the acquisition of a quinine-conditioned flavor avoidance in rats. Physiology & behavior, 2014, Apr-10, Volume: 128 Topics: Animals; Avoidance Learning; Benzazepines; Conditioning, Psychological; Dizocilpine Maleate; Dopamine D2 Receptor Antagonists; Fructose; Male; Naltrexone; Narcotic Antagonists; Quinine; Raclopride; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, Dopamine D2; Receptors, N-Methyl-D-Aspartate; Saccharin; Signal Transduction; Taste	2014
Evaluation of saccharin intake and expression of fructose-conditioned flavor preferences following opioid receptor antagonism in the medial prefrontal cortex, amygdala or lateral hypothalamus in rats. Neuroscience letters, 2014, Apr-03, Volume: 564 Topics: Amygdala; Animals; Conditioning, Psychological; Drinking Behavior; Food Preferences; Fructose; Hypothalamus; Male; Naltrexone; Narcotic Antagonists; Prefrontal Cortex; Rats; Rats, Sprague-Dawley; Receptors, Opioid; Saccharin	2014
Nicotine-induced locomotor sensitization: pharmacological analyses with candidate smoking cessation aids. Addiction biology, 2016, Volume: 21, Issue:2 Topics: Acamprosate; Analysis of Variance; Animals; Antidiuretic Hormone Receptor Antagonists; Bupropion; Dose-Response Relationship, Drug; Fructose; Indoles; Male; Motor Activity; Naltrexone; Nicotine; Nicotinic Agonists; Pyrrolidines; Rats, Wistar; Taurine; Tobacco Use Cessation Devices; Topiramate	2016
Lorcaserin, phentermine topiramate combination, and naltrexone bupropion combination for weight loss: the 15-min challenge to sort these agents out. International journal of clinical practice, 2014, Volume: 68, Issue:12 Topics: Benzazepines; Bupropion; Drug Combinations; Drug Prescriptions; Fructose; Humans; Naltrexone; Obesity; Phentermine; Topiramate; Weight Loss	2014
Pharmacological treatment of obesity in Europe: waiting for the arrival of the white blackbird. Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion, 2014, Volume: 61, Issue:10 Topics: Anti-Obesity Agents; Appetite Depressants; Benzazepines; Bupropion; Clinical Trials as Topic; Drug Approval; Drug Combinations; Europe; Fructose; Humans; Naltrexone; Obesity; Phentermine; Product Surveillance, Postmarketing; Topiramate; United States; United States Food and Drug Administration	2014
Nonincretin drugs in later-stage development. The American journal of managed care, 2014, Volume: 20, Issue:1 Spec No. Topics: Anti-Obesity Agents; Benzazepines; Benzoxazines; Bupropion; Drug Combinations; Drug Labeling; Drugs, Investigational; Fructose; Humans; Naltrexone; Obesity; Phentermine; United States; United States Food and Drug Administration	2014
Dopamine D1 and opioid receptor antagonist-induced reductions of fructose and saccharin intake in BALB/c and SWR inbred mice. Pharmacology, biochemistry, and behavior, 2015, Volume: 131 Topics: Animals; Benzazepines; Dietary Carbohydrates; Dose-Response Relationship, Drug; Fructose; Male; Mice, Inbred BALB C; Mice, Inbred Strains; Naltrexone; Narcotic Antagonists; Receptors, Dopamine D1; Receptors, Opioid; Saccharin; Species Specificity; Sweetening Agents	2015
Review of pharmacotherapy options for the management of obesity. Journal of the American Association of Nurse Practitioners, 2016, Volume: 28, Issue:2 Topics: Benzazepines; Bupropion; Disease Management; Fructose; Humans; Lactones; Liraglutide; Naltrexone; Obesity; Orlistat; Phentermine; Topiramate; United States	2016
Dopamine D1 and opioid receptor antagonists differentially reduce the acquisition and expression of fructose-conditioned flavor preferences in BALB/c and SWR mice. Physiology & behavior, 2015, Nov-01, Volume: 151 Topics: Animals; Benzazepines; Choice Behavior; Conditioning, Psychological; Dopamine Antagonists; Extinction, Psychological; Food Deprivation; Food Preferences; Fructose; Male; Mice, Inbred BALB C; Naltrexone; Narcotic Antagonists; Receptors, Dopamine D1; Species Specificity	2015
Multifaceted academic detailing program to increase pharmacotherapy for alcohol use disorder: interrupted time series evaluation of effectiveness. Addiction science & clinical practice, 2016, 09-15, Volume: 11, Issue:1 Topics: Acamprosate; Adult; Alcohol Deterrents; Alcohol-Related Disorders; Disulfiram; Female; Fructose; Humans; Male; Middle Aged; Naltrexone; Patient Compliance; Taurine; Topiramate; United States; United States Department of Veterans Affairs; Veterans; Young Adult	2016
Obesity Epidemic: Pharmaceutical Weight Loss. Rhode Island medical journal (2013), 2017, Mar-01, Volume: 100, Issue:2 Topics: Anti-Obesity Agents; Benzazepines; Body Mass Index; Bupropion; Drug Combinations; Fructose; Humans; Lactones; Liraglutide; Naltrexone; Obesity; Orlistat; Phentermine; Weight Loss	2017
More Treatments on Deck for Alcohol Use Disorder. JAMA, 2017, Jun-13, Volume: 317, Issue:22 Topics: Acamprosate; Alcohol Deterrents; Alcohol-Related Disorders; Amines; Baclofen; Cyclohexanecarboxylic Acids; Cytidine Diphosphate Choline; Disulfiram; Drug Repositioning; Fructose; Gabapentin; gamma-Aminobutyric Acid; Humans; Mifepristone; Naltrexone; National Institute on Alcohol Abuse and Alcoholism (U.S.); Off-Label Use; Patient Acceptance of Health Care; Taurine; Topiramate; United States; Varenicline	2017